PDCD1 and urinary bladder carcinoma: The clinical efficacies of immunotherapies that target the immune checkpoint programmed cell death 1 receptor (PD-1) and its ligand programmed cell death 1 ligand 1 (PD-L1) have been demonstrated in several malignancies, such as non-small cell lung cancer and bladder cancer [12,13].